Targeted CRO partnerships Epistem operates as a contract research provider with strong preclinical capabilities in oncology, inflammatory, dermatology, autoimmune and GI indications and has a track record with over 200 pharmaceutical and biotech clients, signaling opportunities to partner with mid to large cap pharma seeking specialized preclinical services and toxicity assessment, including GI tox and stem cell assays.

Biomarker and genetics focus The biomarker services division offers GCLP compliant genetic testing, histology, FACS and protein biomarker detection, while the genetics group performs gene expression and DNA genotyping by NGS, microarray and qPCR, including low input and single-cell analyses, presenting cross-selling potential to drug programs needing advanced biomarker readouts and companion diagnostics.

Specialized low input Epistem’s proprietary low input techniques for work with small starting materials and single-cell inputs create a selling point for programs with limited tissue or rare samples, making the firm attractive to projects in early discovery or personalized medicine that require high-sensitivity analyses.

Key personnel leverage Recent leadership hires in business development and commercial direction, along with a growing client base and repeat business, indicate momentum in client acquisition and upsell opportunities; leverage this network to pursue expanded services such as full pipelines from preclinical to translational biomarker programs.

Industry engagement Regular participation in major conferences (AACR, ESMO, Biomarkers) enhances visibility among pharma and biotech buyers, suggesting a strategy to align event participation with targeted outreach and pre-arranged meetings to accelerate sales conversations and generate inbound interest for specific therapeutic areas.